Do Not Increase Melatonin to 10mg
I do not recommend increasing the prolonged-release melatonin dose to 10 mg in this 86-year-old woman, as current evidence does not support doses above 2 mg for insomnia treatment in older adults. 1
Why Higher Doses Are Not Recommended
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline explicitly states a weak recommendation against using melatonin for insomnia treatment, based on trials evaluating 2 mg doses 1. The evidence showed:
- No clinically significant improvement in sleep latency, total sleep time, or wake after sleep onset
- Quality of evidence was very low due to heterogeneity, imprecision, and potential publication bias 2, 1
- Benefits were judged to be approximately equal to harms 1
The Problem with Supraphysiological Dosing
Research demonstrates that higher doses create problems rather than solutions:
- A 4 mg dose (10-fold lower than the proposed 10 mg) produced maximum concentrations of approximately 4000 pg/mL—substantially higher than physiologic levels—and maintained elevated melatonin levels for 10 hours, extending well beyond the typical sleep period 3
- Physiologic dosing (0.3 mg) effectively restored sleep efficiency in older adults with insomnia, while the 3 mg pharmacologic dose induced hypothermia and caused melatonin to remain elevated into daylight hours 4
- Melatonin acts primarily as a chronobiotic whose effects depend more on timing than dose 5
What to Do Instead
Rather than escalating to an unsupported and potentially harmful 10 mg dose, consider this approach:
1. Reassess the Diagnosis
- Verify this is truly primary insomnia and not a circadian rhythm sleep-wake disorder being misclassified 5
- Circadian disorders require phase-targeted treatment, not symptomatic hypnotic approaches
2. Optimize Current Melatonin Use
- Ensure administration is 1-2 hours before bedtime (around 6 PM), not reflexively at bedtime 6, 7, 8
- Verify she's using prolonged-release formulation (immediate-release has different kinetics) 9
- Confirm adequate trial duration (at least 3 weeks) 6, 7
3. Switch to Evidence-Based Alternatives
If melatonin remains ineffective after optimization, transition to medications with stronger evidence in this age group:
- Doxepin 3-6 mg for sleep maintenance insomnia (low-strength evidence, benefits outweigh harms) 1
- Suvorexant 10 mg (lower dose for elderly) for sleep maintenance (moderate-strength evidence) 2, 1
- Temazepam 15 mg for sleep onset and maintenance (moderate-strength evidence, though benzodiazepines carry dementia risk with long-term use) 2, 1
4. Prioritize Non-Pharmacologic Treatment
- Cognitive behavioral therapy for insomnia (CBT-I) is first-line treatment and can facilitate discontinuation of ineffective medications 10
Critical Caveats
- Regulatory inconsistency: Melatonin is not FDA-approved for insomnia, and over-the-counter preparations show substantial variability in actual content 5
- Age considerations: At 86 years, this patient has decreased melatonin clearance, making supraphysiological dosing particularly problematic 3
- Avoid the "natural = safe" fallacy: Melatonin requires the same diagnostic rigor and individualized assessment as any pharmacological intervention 5
The evidence clearly indicates that escalating beyond 2 mg represents dose escalation without efficacy data and risks creating adverse effects from prolonged supraphysiological melatonin levels. If 5 mg (already 2.5 times the studied dose) provides no relief, further dose increases are unlikely to help and may cause harm.